News | January 28, 2024
Eiko LifeSciences inks business agreement with Vivacious Pharmatex
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The deal includes upfront payments, milestone payments and ongoing royalties
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent will supply sintilimab for the collaborated clinical trial
10+ emerging markets, Japan & ANZ transition in final phase
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Subscribe To Our Newsletter & Stay Updated
